The biopharma ecosystem stands at a crossroads. With anemic R&D delivery, failed clinical trials, access challenges, declining valuations, escalating clinical trial costs, patient identification, the hurdles we face are significant. We invite you to join leading experts from academia, biopharma, and the investment community to discuss strategies to navigate these in oncology and rare diseases.